Cargando…
Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience
BACKGROUND: The present study describes our 10-year experience with uveoretinal adverse events that manifest because of chemotherapy. METHODS: A retrospective chart review was performed for all patients who presented to the ophthalmologic department while undergoing systemic chemotherapy between Jul...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785627/ https://www.ncbi.nlm.nih.gov/pubmed/29359539 http://dx.doi.org/10.3346/jkms.2018.33.e55 |
_version_ | 1783295636692533248 |
---|---|
author | Cho, Ah Ran Yoon, Young Hee Kim, June-Gone Kim, Yoon Jeon Lee, Joo Yong |
author_facet | Cho, Ah Ran Yoon, Young Hee Kim, June-Gone Kim, Yoon Jeon Lee, Joo Yong |
author_sort | Cho, Ah Ran |
collection | PubMed |
description | BACKGROUND: The present study describes our 10-year experience with uveoretinal adverse events that manifest because of chemotherapy. METHODS: A retrospective chart review was performed for all patients who presented to the ophthalmologic department while undergoing systemic chemotherapy between July 2005 and June 2015. RESULTS: A total of 55 patients (mean age, 51.2 years, 38 women [69.1%]) suspected of having uveoretinal disease owing to the use of chemotherapeutic agents alone were enrolled. Breast cancer was the predominant disease (36.4%); noninfectious anterior uveitis (21.8%) was the most common condition. Bilateral involvement was observed in 16 patients (29.1%). Although cisplatin (21.8%) was the most commonly used drug, daunorubicin, cytarabine, tamoxifen, toremifene, and imatinib were also frequently used. The median duration until ophthalmologic diagnosis was 208.5 days (range, 19–5,945 days). The proportion of patients with final visual acuity (VA) < 20/40 Snellen VA (0.5 decimal VA) was 32.7%. However, no relationship was observed between final VA < 20/40 and age, sex, therapeutic agents, and metastasis. CONCLUSION: Uveoretinal complications were mostly mild to moderate and exhibited a favorable response to conservative therapy. A considerable number of patients exhibited significant irreversible loss of vision after cessation of the causative chemotherapeutic agent. Ophthalmological monitoring is required during chemotherapy. |
format | Online Article Text |
id | pubmed-5785627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The Korean Academy of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-57856272018-02-12 Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience Cho, Ah Ran Yoon, Young Hee Kim, June-Gone Kim, Yoon Jeon Lee, Joo Yong J Korean Med Sci Original Article BACKGROUND: The present study describes our 10-year experience with uveoretinal adverse events that manifest because of chemotherapy. METHODS: A retrospective chart review was performed for all patients who presented to the ophthalmologic department while undergoing systemic chemotherapy between July 2005 and June 2015. RESULTS: A total of 55 patients (mean age, 51.2 years, 38 women [69.1%]) suspected of having uveoretinal disease owing to the use of chemotherapeutic agents alone were enrolled. Breast cancer was the predominant disease (36.4%); noninfectious anterior uveitis (21.8%) was the most common condition. Bilateral involvement was observed in 16 patients (29.1%). Although cisplatin (21.8%) was the most commonly used drug, daunorubicin, cytarabine, tamoxifen, toremifene, and imatinib were also frequently used. The median duration until ophthalmologic diagnosis was 208.5 days (range, 19–5,945 days). The proportion of patients with final visual acuity (VA) < 20/40 Snellen VA (0.5 decimal VA) was 32.7%. However, no relationship was observed between final VA < 20/40 and age, sex, therapeutic agents, and metastasis. CONCLUSION: Uveoretinal complications were mostly mild to moderate and exhibited a favorable response to conservative therapy. A considerable number of patients exhibited significant irreversible loss of vision after cessation of the causative chemotherapeutic agent. Ophthalmological monitoring is required during chemotherapy. The Korean Academy of Medical Sciences 2018-01-10 /pmc/articles/PMC5785627/ /pubmed/29359539 http://dx.doi.org/10.3346/jkms.2018.33.e55 Text en © 2018 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Cho, Ah Ran Yoon, Young Hee Kim, June-Gone Kim, Yoon Jeon Lee, Joo Yong Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience |
title | Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience |
title_full | Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience |
title_fullStr | Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience |
title_full_unstemmed | Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience |
title_short | Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience |
title_sort | uveoretinal adverse effects presented during systemic anticancer chemotherapy: a 10-year single center experience |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785627/ https://www.ncbi.nlm.nih.gov/pubmed/29359539 http://dx.doi.org/10.3346/jkms.2018.33.e55 |
work_keys_str_mv | AT choahran uveoretinaladverseeffectspresentedduringsystemicanticancerchemotherapya10yearsinglecenterexperience AT yoonyounghee uveoretinaladverseeffectspresentedduringsystemicanticancerchemotherapya10yearsinglecenterexperience AT kimjunegone uveoretinaladverseeffectspresentedduringsystemicanticancerchemotherapya10yearsinglecenterexperience AT kimyoonjeon uveoretinaladverseeffectspresentedduringsystemicanticancerchemotherapya10yearsinglecenterexperience AT leejooyong uveoretinaladverseeffectspresentedduringsystemicanticancerchemotherapya10yearsinglecenterexperience |